For example, reducing pulmonary first-pass elimination without reducing the specific curative effect on IRI-AKI, the level of PINK1 carried by BMSCs, and the verification of the accurate targeting are challenges that should be overcome in the future. This evidence concerns the gene PINK1 and acute kidney injury.